Idorsia enters into exclusive negotiations for global rights to aprocitentan

Ad hoc announcement pursuant to Art. 53 LR

• Company enters into exclusive negotiations with an undisclosed party for global rights to aprocitentan
• Company to streamline the business, resulting in cost containment – consequently, approximately 270 positions globally could become redundant
• Company plans to restructure its outstanding debt

Allschwil, Switzerland – November 27, 2024
Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. Idorsia will receive an exclusivity fee of USD 35 million, which extends Idorsia’s cash runway into 2025. The potential agreement under discussion could include an upfront payment, additional milestone payments, and tiered royalties on sales in return for the transfer of global rights to aprocitentan and certain team members from Idorsia.

André C. Muller, CEO of Idorsia, commented: "I am pleased to announce that we made an important step to reaching a potential agreement for the global rights to aprocitentan. We are targeting signing before the end of 2024 and closing in early 2025, more details will be shared should a final agreement be signed. This is a first and crucial step in our plan to put Idorsia in a financially sustainable position and on the road towards profitability.”

André continued: "In addition, we are implementing initiatives which include cost-containment measures, and steps to restructure our outstanding debt. I am confident that our plan is achievable within the next few months, and that will allow us to shift our focus back to our products. Simply put, we must contain our ambition and restrict our investments until we are generating the revenues from both proprietary and partnered products that will sustain our activities.”

Planned company restructuring
To reach sustainable profitability, the company must focus its efforts, reducing the number of active projects in research and development and preparing some for out-licensing. Consequently, a reduction of the number of employees is envisaged. Depending on the outcome of a consultation process initiated with employee representatives at headquarters, approximately 270 positions globally could become redundant, mainly in Research & Development and support functions at headquarters. Idorsia’s key global functions will continue to be headquartered in Allschwil, Switzerland. The company is committed to minimizing the number of potential redundancies through natural attrition, retirement, transfer along with aprocitentan, and other measures. As part of the ongoing aprocitentan discussions, the company is looking for ways to mitigate the social impact.   The company expects some employees could potentially be offered the opportunity to continue to pursue their efforts to make aprocitentan a success should a final agreement be reached. Upon completion of the consultation process, Idorsia intends to conclude restructuring by the end of 2024, with the cost reduction becoming fully effective by Q2 2025.

Notes to the editor

About aprocitentan
Aprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ET_A and ET_B receptors. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the US. On June 27, 2024, aprocitentan was granted market authorization by the European Commission as JERAYGO™.

About Idorsia
Idorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients.

The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize innovative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has an experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.

Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0)58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as "estimates”, "believes”, "expects”, "may”, "are expected to”, "will”, "will continue”, "should”, "would be”, "seeks”, "pending” or "anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

• Press Release PDF